June Off to a Poor ...
Health Care: Drugs
AMAG Pharmaceuticals Inc. (AMAG: NASDAQ)
$13.58 -0.45 | -3.21%
06/01/12 - 04:00 PM ET
Ratio Comparisons
| Company | Industry | S&P 500 | |
| Valuation Ratios | |||
|---|---|---|---|
| P/E Ratio (TTM) | n.a. | 173.50 | 17.70 |
| P/E High - Last 5 Yrs | n.a. | n.a. | 67.70 |
| P/E Low - Last 5 Yrs | n.a. | n.a. | 12.50 |
| Beta | 0.62 | 0.96 | 0.98 |
| Price to Sales (TTM) | 4.58 | 4.16 | 1.42 |
| Price to Book (MRQ) | 1.71 | 3.92 | 2.41 |
| Price to Tangible Book (MRQ) | 1.71 | 5.44 | 5.08 |
| Price to Cash Flow (TTM) | -4.70 | 46.50 | 9.80 |
| Price to Free Cash Flow (TTM) | -5.40 | -315.20 | 17.40 |
| Dividends | |||
| Dividend Yield (%) | 0.00 | 0.30 | 2.10 |
| Dividend Yield - 5 Yr Avg (%) | n.a. | 0.30 | 2.20 |
| Dividend 5 Yr Growth Rate (%) | n.a. | 35.82 | -0.76 |
| Payout Ratio (TTM) | 0.00 | 63.00 | 30.00 |
| Sales (MRQ) vs Qtr 1 Yr Ago (%) | 15.70 | 6.80 | 11.80 |
| Sales (TTM) vs TTM 1 Yr Ago (%) | -7.50 | -3.40 | 9.20 |
| Growth Rates (%) | |||
| Sales - 5 Yr Growth Rate (%) | 117.28 | 0.00 | 1.79 |
| EPS (MRQ) vs Qtr 1 Yr Ago (%) | n.a. | -93.00 | 17.50 |
| EPS (TTM) vs TTM 1 Yr Ago (%) | n.a. | -93.00 | 17.50 |
| EPS - 5 Yr Growth Rate (%) | n.a. | n.a. | -1.66 |
| Capital Spending - 5 Yr Growth Rate (%) | -8.28 | -9.04 | -1.17 |
| Financial Strength | |||
| Quick Ratio (MRQ) | 5.50 | 2.90 | 1.10 |
| Current Ratio (MRQ) | 6.00 | 3.60 | 1.60 |
| LT Debt to Equity (MRQ) | 0.00 | 0.04 | 0.82 |
| Total Debt to Equity (MRQ) | 0.00 | 0.09 | 0.96 |
| Interest Coverage (TTM) | n.a. | 22.20 | 5.50 |
| Profitability Ratios (%) | |||
| Gross Margin (TTM) | 93.40 | 62.80 | 46.90 |
| Gross Margin - 5 Yr Avg | 96.40 | 63.90 | 47.70 |
| EBITD Margin (TTM) | -95.00 | 15.20 | 18.90 |
| EBITD - 5 Yr Avg | -242.44 | 0.00 | 0.00 |
| Pre-Tax Margin (TTM) | n.a. | 8.80 | 12.10 |
| Pre-Tax Margin - 5 Yr Avg | n.a. | -0.50 | 10.30 |
| Management Effectiveness (%) | |||
| Net Profit Margin (TTM) | -1.06 | 0.03 | 0.09 |
| Net Profit Margin - 5 Yr Avg | n.a. | -6.20 | 7.00 |
| Return on Assets (TTM) | -26.50 | 1.90 | 3.10 |
| Return on Assets - 5 Yr Avg | -27.20 | -4.20 | 2.50 |
| Return on Investment (TTM) | -39.00 | 2.40 | 7.90 |
| Return on Investment - 5 Yr Avg | -33.40 | -5.80 | 6.50 |
| Efficiency | |||
| Revenue/Employee (TTM) | 364,046.00 | 229,628.00 | 449,376.00 |
| Net Income/Employee (TTM) | -386,149.00 | 6,227.00 | 39,003.00 |
| Receivable Turnover (TTM) | 9.00 | 7.10 | 7.60 |
| Inventory Turnover (TTM) | 0.30 | 3.00 | 8.30 |
| Asset Turnover (TTM) | 0.20 | 0.70 | 0.40 |
Portfolios with AMAG
- Portfolio NameUser Type
- ContributorStocks Rising On Unusual Vo...
- ContributorBreakout Stocks Of The Week...
- UserPelican Watch
- UserPART 1 JPMorgan 28th Annual...
- UserPART 1 JPMorgan 27th Annual...
- Userileana
- UserShawen Portfolio 1
- Userfiallo Portfolio 1
- UserTSimao Portfolio 1
- Usersggrimsley
Latest AMAG Headlines from TheStreet
- 8 Stocks Rising on Huge Volume 04.20.12 | 01:04 pm
- Biotech Stock Mailbag: Oncothyreon, Amag, Keryx Hate Mail 03.09.12 | 05:03 am
- Insiders Trading AMAG, CLWR, GTXI 03.06.12 | 10:03 am
- More Biotech Lessons Learned From JPM 2012 01.13.12 | 06:01 am
- The Next Big Thing In Biotech: 2012 Outlook
01.06.12 | 05:01 am - 5 Stocks Poised for Breakouts 11.07.11 | 09:11 am
- Next Step for Amag's Board: Fire CEO, Sell the Company. 10.21.11 | 11:10 am
- Biotech Stock Mailbag: Keryx Pharma 10.14.11 | 06:10 am
- Activist Fund Manager Ups Stake in Amag Pharma to Stop Merger With Allos 10.10.11 | 10:10 am
- Spectrum Pharma Said to Make Bid for Allos 09.21.11 | 11:09 am
Press Releases for AMAG
- AMAG Pharmaceuticals, Inc. To Present At Upcoming Investor Conferences - Business Wire 05.29.12 | 05:05 pm
- AMAG Pharmaceuticals Appoints William Heiden As President And Chief Executive Officer - Business Wire 05.09.12 | 04:05 pm
- AMAG Pharmaceuticals, Inc. To Host Conference Call On May 1, 2012 At 4:30 P.m. ET To Discuss Financial Results For The Quarter Ended March 31, 2012 - Business Wire 04.24.12 | 04:04 pm
- AMAG Pharmaceuticals Announces A Positive CHMP Opinion For The Approval Of Ferumoxytol In Europe For The Treatment Of Iron Deficiency Anemia In Adult Patients With Chronic Kidney Disease - Business Wire 04.20.12 | 09:04 am
- AMAG Pharmaceuticals Announces Preliminary Results From Its Phase III Study Evaluating Feraheme Compared To IV Iron Sucrose In Patients With Iron Deficiency Anemia - Business Wire 03.07.12 | 04:03 pm
- AMAG Pharmaceuticals, Inc. To Host Conference Call On March 7, 2012 At 4:30 P.m. ET To Discuss Feraheme Clinical Trial Results - Business Wire 03.06.12 | 04:03 pm
- AMAG Announces Fourth Quarter And Year End 2011 Financial Results - Business Wire 03.05.12 | 04:03 pm
- AMAG Pharmaceuticals, Inc. To Present At The 24th Annual ROTH Conference - Business Wire 03.02.12 | 04:03 pm
- AMAG Pharmaceuticals, Inc. To Host Conference Call On March 5, 2012 At 4:30 P.m. ET To Discuss Financial Results For The Fourth Quarter And Year Ended 2011 - Business Wire 02.23.12 | 04:02 pm
- AMAG Pharmaceuticals, Inc. To Present At Upcoming Investor Conferences - Business Wire 02.13.12 | 04:02 pm
Partner Headlines for AMAG
- AMAG Beats Riding on Feraheme Sales - Analyst Blog - Zacks 05.02.12 | 10:05 am
- AMAG Pharmaceuticals Reports Mixed Q4 Results - Benzinga 03.05.12 | 04:03 pm
- AMAG Pharmaceuticals Reports Mixed Q4 Results - Benzinga 03.05.12 | 04:03 pm
- Israel Englander's Stock Picks With Insider Purchases - Seeking Alpha 01.18.12 | 09:01 am
- 17 Breakout Stocks Boosted By Insiders - Seeking Alpha 12.30.11 | 04:12 pm
- McNicoll Lewis & Vlak Raises PT on AMAG Pharmaceuticals to $23 - Benzinga 12.12.11 | 01:12 pm
- Mid-Day Update: Stocks Pare Some Early Losses; Unemployment Claims Lift Sentiment - NASDAQ 11.17.11 | 05:11 pm
- Loss Shrinks at AMAG, CEO Departs - Analyst Blog - Zacks 11.08.11 | 10:11 am
- Zacks #1 Rank Additions for Wednesday - Tale of the Tape - Zacks 10.26.11 | 09:10 am
- Stocks Rally on European Debt Summit Optimism; December Crude Surges Over 2% - NASDAQ 10.21.11 | 04:10 pm
